Skip to main content
Explore URMC

Wilmot Cancer Institute Logo

menu
Edward M. Messing, M.D.
Edward M. Messing, M.D.

Edward M. Messing, M.D.

Urology — Oncology — Urology

Accepting New Patients

Edward M. Messing, M.D.

Urology — Oncology — Urology

Accepting New Patients


Locations

Strong Memorial Hospital
601 Elmwood Ave.
Rochester, NY 14642
Get Directions

phone

Appointments

(585) 275-8762

print

Fax

(585) 273-1068

About Me

I chose this field because half of all cancers in men – and almost 20% in women – arise in urologic organs and are treated by urologists. Specializing in urologic oncology is a way of helping many people.

Since I believe that an informed patient makes the wisest decisions regarding treatment, I spend much time educating my patients about their disease and options for treatment. My approach to patient care is individualized, both in terms of treatments offered and recommended, and in terms of the patient's and his or her family's goals. Treating bladder, kidney, prostate and testicular cancer are among my areas of expertise. I also hold several research grants and patents related to the field of urologic cancer.

Conditions I Treat:

- Bladder cancer
- Kidney cancer
- Prostate cancer
- Testicular cancer
- Adrenal cancer
- Penile cancer
- Scrotal cancer
- Ureteral cancer
- Urethral cancer

Credentials

Education:

MD | New York University School of Medicine — 1972

Post-doctoral Training & Residency:

Internship in Surgery at Bellevue Hospital Center — 1972 - 1973
Residency in Surgery at Bellevue Hospital Center — 1973 - 1974
Residency in Urology at Stanford University School of Medicine — 1974 - 1978

Research

Dr. Messing is an internationally renowned expert in all facets of urologic oncology, both as a clinician/surgeon, and as a clinical, translational and basic researcher.

His research contributions have ranged from enhancing our knowledge about the basic molecular biology and genetics of development and progression of cancers of the bladder, prostate and kidney, and bringing these studies to fruition for the detection, prevention and treatment of these diseases. He has also designed and conducted landmark phase III clinical trials for each of these cancers and has carried out the first
screening trial for bladder cancer in a general population. Important work has included defining the roles of epidermal growth factor (EGF) and its cell surface receptor in urothelial carcinogenesis and progression, investigating polyamine synthesis inhibition as a means to prevent bladder and prostate cancers, in large phase III clinical trials studying DFMO's ability to prevent bladder cancer's recurrence, the timing of androgen deprivation therapy (ADT) in treating regionally advanced completely resected prostate cancer, and the effectiveness of adjuvant alpha interferon for completely resected,
locally extensive, renal cell carcinoma. He has also contributed importantly to trials testing various forms of intravesical therapy for high risk, non-muscle invading bladder cancer, and the value of radiation therapy after prostatectomy for stage pT3 prostate cancer. He has demonstrated the feasibility of screening for bladder cancer (using hematuria reagent strips) and has worked on the development and testing of several molecular markers for the detection of bladder cancer.

Much of the above mentioned work continues, but currently he is also investigating gender disparities in bladder cancer's incidence and outcome. These efforts have ranged from investigations using large, national data bases, to molecular studies in cells and transgenic animal models. Additionally, he along with his basic science collaborators are investigating the preventative and therapeutic roles of nuclear transcription factors, vitamins and related molecules in prevention and treatment of prostate and bladder cancer. Furthermore, his clinical trial work
continues as the study coordinator (PI) of a large phase III clinical trial of immediate post TURBT intravesical instillation therapy for prevention of recurrence of low risk bladder cancer.

Publications:

Silvers CR, Liu YR, Wu CH, Miyamoto H, Messing EM, Lee YF. "Identification of extracellular vesicle periostin as a urinary biomarker of muscle invasive bladder cancer progression". Oncotarget. 2016; Apr 26;7(17):23335-45.

Baack Kukreja JE, Kiernan M, Schempp B, Siebert A, Hontar A, Dolan J, Noyes K, Dozier A, Ghazi A, Rashid HH, Wu G, Messing. "Quality improvement in cystectomy care with enhanced recovery (QUICCER Study)". EMBJU Int. 2016; April 29.

Shang Z, Li Y, Hsu I, Zhang M, Tian J, Wen S, Han R, Messing EM, Chang C, Niu Y, Yeh S. "Targeting estrogen/estrogen receptor alpha will enhance Bacillus Calmette-Guerin efficacy in bladder cancer". Oncotarget. 2016; 15doi: 10.18632/oncotarget.8756.

View All Publications